Copper-catalysed cross-coupling affected by the Smiles rearrangement: a new chapter on diversifying the synthesis of chiral fluorinated 1,4-benzoxazine derivatives

Saba Alapoura, Deresh Ramjugernathb and Neil A. Koorbanally*a
aSchool of Chemistry, University of KwaZulu-Natal, Private Bag X54001, Durban 4000, South Africa. E-mail: koorbanally@ukzn.ac.za
bSchool of Chemical Engineering, University of KwaZulu-Natal, Private Bag X54001, Durban 4000, South Africa

Received 14th September 2015 , Accepted 25th September 2015

First published on 28th September 2015


Abstract

Synthesis of different chiral fluorinated Boc-[1,4]benzoxazins from their open chain precursors were investigated. The NMR spectra and crystallographic data showed the presence of the Smiles Rearrangement (SR) followed by copper catalysed coupling. The influence of the Boc protecting group, solvent, base, catalyst and the conformational changes of adducts was explored in detail by careful reaction optimization. No product was obtained in the absence of Boc, indicating its crucial role. Finally, a new mechanism for the SR copper catalysed ring closure was proposed.


Benzoxazines exist in many drugs and herbicides, and are widely used as building blocks of bioactive molecules. They exhibit interesting biological and pharmaceutical properties such as progesterone receptor (PR) modulation, antianxiety, anti-HIV, agonist and antagonist activities.1–4 Particularly, chiral dihydrobenzo[1,4]oxazines attracted much attention due to their interesting biological activities.5,6 Chiral dihydrobenzo[1,4]oxazines are also employed as catalysts for the asymmetric transfer hydrogenation of α,β-unsaturated aldehydes.7

Fluorine atoms contained in the core structure of a drug results in enhancement of several biological properties such as solubility, lipophilicity, metabolic stability and binding selectivity.8 Levofloxacin, ciprofloxacin, norfloxacin and efavirenz are examples of pharmaceutical drugs containing a fluorine atom together with dihydrobenzo[1,4]oxazines in the same molecule.8–10

Consequently, a wide range of synthetic procedures have been developed for the synthesis of these fluorinated chiral benzoxazines. These procedures include direct cyclization using a metal catalyst such as Pd in the Buchwald–Hartwig coupling reaction11 and the copper-catalysed intramolecular direct ring closure,12 a biocatalytic method13 and several other older methods.14–18

Rearrangement reactions are generally undesired, but in many instances can be favourable since they are able to facilitate the synthesis of synthetically complicated chemicals.19 Additionally, these reactions provide an opportunity to synthesise organic molecules that were not possible previously.

The Smiles Rearrangement (SR) has been used in the synthesis of different benzoxazinones.20–23 To the best of our knowledge there have been no reports of this rearrangement in the synthesis of benzoxazines. In spite of the wealth of literature pertaining to SR, there is still a gap in the literature with regard to studies on the conformational effect on the copper catalysed ring closure via SR. It is well accepted that conformations of precursors can play a crucial role in chemical reactions and biological activity.24–30 As such, there is a need to explore this aspect further.

The initial aim of our work was to synthesise levofloxacin's precursor (6fi) via a copper catalysed ring closure, but surprisingly the interruption by the SR was detected in all derivatives. Further investigation led us to provide a new insight to this rearrangement. The effects of conformational change as well as the presence of fluorine in novel derivatives of benzoxazines were investigated by NMR and X-ray crystallography. These studies helped us to propose a new mechanism for the one pot SR-ring closure reaction of benzoxazine type compounds. Herein we report an operationally simple and economic technique for the synthesis of enantiomerically pure fluorinated [1,4]-benzoxazines assisted by the SR and involving a copper mediated intramolecular ring closure, which can be considered a novel procedure in comparison to the existing literature.

Commercially available alaninol 1 was protected with Boc via standard procedures11 to give 2, which was transformed to a cyclic sulfamidate 3 over two steps with 90% overall yield.11 The reaction of 3 and phenol 4 afforded the product 5 by nucleophilic cleavage in 98% yield.11 The reaction of 5 with a catalytic amount of copper(II) acetate (20 mol%) at 90 °C in (undried) NMP in the presence of Cs2CO3 (3 eq.) provided Boc-[1,4]benzoxazin 6 by replacing the leaving group X1 (either Br, I or F depending on the substrate) (Scheme 1, Table 1).


image file: c5ra18897k-s1.tif
Scheme 1 Synthesis of Boc-[1,4]benzoxazin 6.
Table 1 Synthesis of different Boc-benzoxazine via SR copper catalyzed ring closure. (Temperature: 90 °C)

image file: c5ra18897k-u1.tif

No. Adduct (5) (yielda %) Boc-[1,4]benzoxazine (yielda %)b,c
a Isolated yield (%).b Temperature: 90 °C.c The reaction time for all reactions is 24 hours.
1 image file: c5ra18897k-u2.tif image file: c5ra18897k-u3.tif
2 image file: c5ra18897k-u4.tif image file: c5ra18897k-u5.tif
3 image file: c5ra18897k-u6.tif image file: c5ra18897k-u7.tif
4 image file: c5ra18897k-u8.tif image file: c5ra18897k-u9.tif
5 image file: c5ra18897k-u10.tif image file: c5ra18897k-u11.tif
6 image file: c5ra18897k-u12.tif image file: c5ra18897k-u13.tif
7 image file: c5ra18897k-u14.tif image file: c5ra18897k-u15.tif
8 image file: c5ra18897k-u16.tif image file: c5ra18897k-u17.tif
9 image file: c5ra18897k-u18.tif image file: c5ra18897k-u19.tif


On inspection of the 13C and 19F NMR data of the product 6f from the precursor 5h (available in the ESI), it was apparent that the expected 6fi (Scheme 2) did not form since there was a missing C–F resonance in the 13C NMR spectrum and only a single fluorine resonance was observed in the 19F NMR spectrum. The optimized reaction conditions were applied to 5d and the same observation was found in the spectra of 6c. Instead of 6ci (Scheme 2), the rearranged compound (6c) was found to be the actual structure. This rearrangement, where the stronger F base acts as a leaving group, can be categorized as a SR that typically occurs in the presence of base in polar solvents.6,31,32 Some reports have shown that Cu was essential for the SR ring closure to occur.6,33–36


image file: c5ra18897k-s2.tif
Scheme 2 Synthesis of Boc-[1,4]benzoxazin 6 interrupted by SR.

Considerable optimization (available in ESI) showed that undried NMP (N-methyl-2-pyrrolidone) provided the best yield amongst other polar aprotic solvents. These results also indicated that Cu(OAc)2·H2O was the best catalyst amongst other copper sources. Control experiments in the absence of ligand revealed that Cu(OAc)2·H2O alone was capable of this catalytic performance and application of an external ligand poisoned the reactions. In addition, no product was formed in the absence of copper, indicating its importance in the mechanism of the reaction. Various bases were also tested and amongst these, Cs2CO3 showed the best results. This was in agreement with other reports.6,31,35,37

The reactions were repeated with the optimised conditions at room temperature instead of 90 °C. Surprisingly, the coupling reaction on 5d and 5h proceeded to 6c and 6f with 90% yield at room temperature, while 5a and 5b proceeded to 6a, and 5e and 5f to 6d at 90 °C only and no product was observed at room temperature (Table 1). With the precursors 5c, 5g and 5i, the products 6b, 6e and 6g could not be formed even at 90 °C. This observation prompted us to study the conformation of adducts in the reaction in order to gain an insight into how the products were formed.

The presence of an iodine or bromine atom in the ortho position to the oxygenated side without further substitution (5a, 5b, 5e and 5f) provided almost the same yield for the cyclized products 6a and 6d (∼85%) (Table 1). The highest yield was obtained for 6e (98%) with the 5h precursor. The other precursor with an ortho positioned F atom, 5d also had a similar yield of 96%. Therefore, it can be concluded that electron-withdrawing effect of fluorine in the ortho-position of the aromatic ring stabilizes the formed intermediate (Meisenheimer complex 5h(c) in Scheme 3) and therefore, the highest yields were obtained for 6c and 6f.38 Zhao et al. in 2012 also showed that strong electron-withdrawing groups on the aromatic rings increase the yields of SR.31


image file: c5ra18897k-s3.tif
Scheme 3 Plausible catalytic cycle for formation of Boc-[1,4]benzoxazin through the SR copper catalyzed ring closure reaction.

It is likely that the SR copper catalysed ring closure reaction in this study may follow the proposed mechanism in Scheme 3. In this proposed mechanism, the proton of the amide was removed from 5h(a) in the presence of Cs2CO3 as a base (Scheme 3). This is followed by a nucleophilic substitution of the nitrogen onto the aromatic ring producing 5h(d). In the final step, the resulting nucleophilic oxygen in the side chain substitutes the ortho positioned F atom to yield the product 6f.

The existence of different parameters seems to have a direct impact on the initiation of this reaction. The presence of the Boc protecting group seems to play a crucial role in the SR.39 To prove this hypothesis, we applied the optimised reaction conditions on deprotected 5h and observed that no cyclisation took place. Furthermore, it is suggested that the presence of a carbonyl group in the neighbouring NH (amide group) increases its nucleophilic effect in the SR.39 It is highly likely that this is the reason why there are no reports on the presence of SR for 1,4-benzoxazine, while this rearrangement was frequently reported for benzoxazinones.

Cu(OAc)2 and Cs2CO3 are two other important reagents needed for this rearrangement to occur. The presence of ionic Cu plays a role in increasing the acidity of the amide proton and makes its deprotonation via Cs2CO3 easier.35,40

It is also well accepted that the localized negative charge on the nitrogen in our study increases its nucleophilic strength.39 Polar aprotic solvents such as DMF and NMP are frequently used in the SR, which is in a good agreement with our optimized data.34,35 It is also suggested that these types of solvents stabilize the Meisenheimer complex and help improve the results.35

This copper catalysed coupling reaction is known to occur through the presence of Cu(I). This is supported by literature, which reports that Cu(II) and Cu(0) as a source of Cu will be transformed to Cu(I).41,42 There are also reports that Cu(II) performed better than Cu(I) based on the selected conditions of the reaction.36,43

In addition, when there is competition between Br and F, the expected leaving group is assumed to be Br, the better of the two leaving groups. This did not occur in our experiments. The presence of steric hindrance between the Boc protecting group (5h(f) Scheme 3) and Br with a large atomic radius (in comparison to F) causes the oxygen to substitute the F instead of Br on the aromatic ring.

Based on the proposed mechanism in Scheme 3, this conformer (5h) facilitated the SR by shortening the distance between the nucleophile and the electrophile (ipso carbon) (Fig. 1) for the occurrence of nucleophilic substitution. These desirable conformations of 5d and 5h assist these reactions, so much so that these reactions could proceed at room temperature with high yield.


image file: c5ra18897k-f1.tif
Fig. 1 Crystal structure of 5e, 5f and 5h and the distances between the ipso carbon and nitrogen.

As can be seen from Fig. 1, 5h (and probably 5d) possess a folded structure. Based on a review published by O'Hagan,44 it can be proposed that the fluorine atoms in the aromatic ring of adduct 5g (and 5d) is situated in an ideal position for a dipole–dipole interaction, which results in the conformer shown in Fig. 1 and 2. Since fluorine atoms are well-known π donors, this interaction can be due to hyper-conjugation of the highly polarized C–F bonds, which is stabilized by the π system of the aromatic ring and provide the gauche conformer in 5g (and 5d) (Fig. 2(a)).45–47


image file: c5ra18897k-f2.tif
Fig. 2 (a) Gauche conformer (from crystal structure of 5g) (b) anti conformer (from crystal structure of 5d and 5e).

Conclusions

The new synthesis procedure for chiral [1,4]-benzoxazin derivatives containing F atoms as well as other halogens in different positions of the aromatic ring via the copper catalyzed SR ring closure provided valuable information about the effect of the SR on the synthesis and diversification of these valuable chemicals. The optimization reaction conditions as well as the proposed mechanism indicated the importance of the Boc protecting group, since this reaction could not proceed in its absence. Application of polar aprotic solvents seems to facilitate this reaction and enhances the final yield. In addition, presence of both a copper source and Cs2CO3 is crucial for this reaction to occur (Scheme 3). Finally, the reaction of adducts 5d and 5h (Fig. 1) with folded structures in the gauche conformation (from crystallographic data) made it possible for these reactions to occur at room temperature.

Acknowledgements

This research was supported by grants from the National Research Foundation (NRF), South Africa and was supported by the South African Research Chairs Initiative of the Department of Science and Technology. We thank Dr Bernard Owaga and Mr Sizwe Zamisa for assistance with X-Ray crystallography.

References

  1. N. Dias, J. F. Goossens, B. Baldeyrou, A. Lansiaux, P. Colson, A. Di Salvo, J. Bernal, A. Turnbull, D. J. Mincher and C. Bailly, Bioconjugate Chem., 2005, 16, 949–958 CrossRef CAS PubMed.
  2. S. J. Hays, B. W. Caprathe, J. L. Gilmore, N. Amin, M. R. Emmerling, W. Michael, R. Nadimpalli, R. Nath, K. J. Raser, D. Stafford, D. Watson, K. Wang and J. C. Jaen, J. Med. Chem., 1998, 41, 1060–1067 CrossRef CAS PubMed.
  3. S. Jana, A. Ashokan, S. Kumar, A. Verma and S. Kumar, Org. Biomol. Chem., 2015, 13, 8411–8415 CAS.
  4. P. Zhang, E. A. Terefenko, A. Fensome, Z. Zhang, Y. Zhu, J. Cohen, R. Winneker, J. Wrobel and J. Yardley, Bioorg. Med. Chem. Lett., 2002, 12, 787–790 CrossRef CAS.
  5. B. Achari, S. B. Mandal, P. K. Dutta and C. Chowdhury, Synlett, 2004, 2449–2467 CAS.
  6. E. Feng, H. Huang, Y. Zhou, D. Ye, H. Jiang and H. Liu, J. Org. Chem., 2009, 74, 2846–2849 CrossRef CAS PubMed.
  7. C. Ebner and A. Pfaltz, Tetrahedron, 2011, 67, 10287–10290 CrossRef CAS PubMed.
  8. S. Purser, P. R. Moore, S. Swallow and V. Gouverneur, Chem. Soc. Rev., 2008, 37, 320–330 RSC.
  9. V. V. Komnatnyy, W.-C. Chiang, T. Tolker-Nielsen, M. Givskov and T. E. Nielsen, Angew. Chem., Int. Ed., 2014, 53, 439–441 CrossRef CAS PubMed.
  10. S. Atarashi, S. Yokohama, K. I. Yamazaki, K. I. Sakano, M. Imamura and I. Hayakawa, Chem. Pharm. Bull., 1987, 35, 1896–1902 CrossRef CAS.
  11. J. F. Bower, P. Szeto and T. Gallagher, Org. Lett., 2007, 9, 3283–3286 CrossRef CAS PubMed.
  12. M. K. Parai and G. Panda, Tetrahedron Lett., 2009, 50, 4703–4705 CrossRef CAS PubMed.
  13. M. Lopez-Iglesias, E. Busto, V. Gotor and V. Gotor-Fernandez, J. Org. Chem., 2015, 80, 3815–3824 CrossRef CAS PubMed.
  14. S. Atarashi, H. Tsurumi, T. Fujiwara and I. Hayakawa, J. Heterocycl. Chem., 1991, 28, 329–331 CrossRef CAS PubMed.
  15. J. Balint, G. Egri, E. Fogassy, Z. Bocskei, K. Simon, A. Gajary and A. Friesz, Tetrahedron: Asymmetry, 1999, 10, 1079–1087 CrossRef CAS.
  16. S. B. Kang, E. J. Ahn, Y. Kim and Y. H. Kim, Tetrahedron Lett., 1996, 37, 9317–9320 CrossRef CAS.
  17. L. A. Mitscher, P. N. Sharma, D. T. W. Chu, L. L. Shen and A. G. Pernet, J. Med. Chem., 1987, 30, 2283–2286 CrossRef CAS.
  18. K. Satoh, M. Inenaga and K. Kanai, Tetrahedron: Asymmetry, 1998, 9, 2657–2662 CrossRef CAS.
  19. T. J. Snape, Chem. Soc. Rev., 2008, 37, 2452–2458 RSC.
  20. I. G. C. Coutts and M. R. Southcott, J. Chem. Soc., Perkin Trans. 1, 1990, 767–771 RSC.
  21. J. Kang, K. H. Kam, M. Ghate, Z. Hua, T. H. Kim, C. R. Reddy, S. Chandrasekhar and D. S. Shin, ARKIVOC, 2008, 67–76 CAS.
  22. S. Xia, J.-Q. Liu, X.-H. Wang, Y. Tian, Y. Wang, J.-H. Wang, L. Fang and H. Zuo, Bioorg. Med. Chem. Lett., 2014, 24, 1479–1483 CrossRef CAS PubMed.
  23. H. Zuo, L. Meng, M. Ghate, K. H. Hwang, Y. K. Cho, S. Chandrasekhar, C. R. Reddy and D. S. Shin, Tetrahedron Lett., 2008, 49, 3827–3830 CrossRef CAS PubMed.
  24. J. I. Seeman, Chem. Rev., 1983, 83, 83–134 CrossRef CAS.
  25. L. Agocs, G. G. Briand, N. Burford, T. S. Cameron, W. Kwiatkowski and K. N. Robertson, Inorg. Chem., 1997, 36, 2855–2860 CrossRef CAS PubMed.
  26. C. M. Dobson, Nature, 2003, 426, 884–890 CrossRef CAS PubMed.
  27. X.-B. Wang, J. Yang and L.-S. Wang, J. Phys. Chem. A, 2008, 112, 172–175 CrossRef CAS PubMed.
  28. M. Nishizaka, T. Mori and Y. Inoue, J. Phys. Chem. Lett., 2010, 1, 2402–2405 CrossRef CAS.
  29. T. Lei, X. Xia, J.-Y. Wang, C.-J. Liu and J. Pei, J. Am. Chem. Soc., 2014, 136, 2135–2141 CrossRef CAS PubMed.
  30. M. D. Farahani, B. Honarparvar, F. Albericio, G. E. M. Maguire, T. Govender, P. I. Arvidsson and H. G. Kruger, Org. Biomol. Chem., 2014, 12, 4479–4490 CAS.
  31. Y. Zhao, Y. Wu, J. Jia, D. Zhang and C. Ma, J. Org. Chem., 2012, 77, 8501–8506 CrossRef CAS PubMed.
  32. T. J. Snape, Chem. Soc. Rev., 2008, 37, 2452–2458 RSC.
  33. M. O. Kitching, T. E. Hurst and V. Snieckus, Angew. Chem., Int. Ed., 2012, 51, 2925–2929 CrossRef CAS PubMed.
  34. T. E. Hurst, M. O. Kitching, L. C. R. M. da Frota, K. G. Guimaraes, M. E. Dalziel and V. Snieckus, Synlett, 2015, 26, 1455–1460 CrossRef CAS.
  35. N. C. Ganguly, P. Mondal, S. Roy and P. Mitra, RSC Adv., 2014, 4, 55640–55648 RSC.
  36. P. Sang, M. Yu, H. Tu, J. Zou and Y. Zhang, Chem. Commun., 2013, 49, 701–703 RSC.
  37. L. Fang, H. Zuo, Z. B. Li, X. Y. He, L. Y. Wang, X. Tian, B. X. Zhao, J. Y. Miao and D. S. Shin, Med. Chem. Res., 2011, 20, 670–677 CrossRef CAS.
  38. J. Hornback, Organic Chemistry, Cengage Learning, 2005 Search PubMed.
  39. J. F. Bunnett and R. E. Zahler, Chem. Rev., 1951, 49, 273–412 CrossRef CAS.
  40. B. F. G. Johnson, Inorganic Chemistry of the Transition Elements, Chemical Society, 1977 Search PubMed.
  41. X. Ribas and I. Gueell, Pure Appl. Chem., 2014, 86, 345–360 CrossRef CAS.
  42. C. Sambiagio, S. P. Marsden, A. J. Blacker and P. C. McGowan, Chem. Soc. Rev., 2014, 43, 3525–3550 RSC.
  43. S. Li, Z. Li and J. Wu, Adv. Synth. Catal., 2012, 354, 3087–3094 CrossRef CAS PubMed.
  44. D. O'Hagan, Chem. Soc. Rev., 2008, 37, 308–319 RSC.
  45. P. R. Rablen, R. W. Hoffmann, D. A. Hrovat and W. T. Borden, J. Chem. Soc., Perkin Trans. 2, 1999, 1719–1726 RSC.
  46. L. Goodman, H. B. Gu and V. Pophristic, J. Phys. Chem. A, 2005, 109, 1223–1229 CrossRef CAS PubMed.
  47. C. Sparr, E. Salamanova, W. B. Schweizer, H. M. Senn and R. Gilmour, Chem.–Eur. J., 2011, 17, 8850–8857 CrossRef CAS PubMed.

Footnote

Electronic supplementary information (ESI) available: Experimental details, 1H NMR spectra, 13C NMR spectrum, 2D NMR spectra, HRMS profile and CIF files of crystallographic data. CCDC 1408545, 1408546, 1408549 and 1419382. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c5ra18897k

This journal is © The Royal Society of Chemistry 2015
Click here to see how this site uses Cookies. View our privacy policy here.